INDP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INDP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Warning Sign:
Piotroski F-Score of 1 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Indaptus Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Indaptus Therapeutics's Piotroski F-Score or its related term are showing as below:
During the past 4 years, the highest Piotroski F-Score of Indaptus Therapeutics was 3. The lowest was 1. And the median was 2.
The historical data trend for Indaptus Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Piotroski F-Score | N/A | N/A | 3.00 | 1.00 |
Indaptus Therapeutics Quarterly Data | |||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Piotroski F-Score | Get a 7-Day Free Trial | 3.00 | N/A | 3.00 | 1.00 | 1.00 |
For the Biotechnology subindustry, Indaptus Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Indaptus Therapeutics's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Dec23) TTM: | Last Year (Dec22) TTM: |
Net Income was -4.253 + -3.245 + -3.922 + -4.003 = $-15.42 Mil. Cash Flow from Operations was -4.962 + -2.107 + -3.734 + -2.602 = $-13.41 Mil. Revenue was 0 + 0 + 0 + 0 = $0.00 Mil. Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil. Average Total Assets from the begining of this year (Dec22) to the end of this year (Dec23) was (28.064 + 23.145 + 20.845 + 17.794 + 14.924) / 5 = $20.9544 Mil. Total Assets at the begining of this year (Dec22) was $28.06 Mil. Long-Term Debt & Capital Lease Obligation was $0.07 Mil. Total Current Assets was $14.00 Mil. Total Current Liabilities was $2.77 Mil. |
Net Income was -3.365 + -3.836 + -3.466 + -3.656 = $-14.32 Mil. Revenue was 0 + 0 + 0 + 0 = $0.00 Mil. Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil. Average Total Assets from the begining of last year (Dec21) to the end of last year (Dec22) was (40.577 + 37.087 + 34.059 + 30.453 + 28.064) / 5 = $34.048 Mil. Total Assets at the begining of last year (Dec21) was $40.58 Mil. Long-Term Debt & Capital Lease Obligation was $0.00 Mil. Total Current Assets was $27.24 Mil. Total Current Liabilities was $3.43 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Indaptus Therapeutics's current Net Income (TTM) was -15.42.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Indaptus Therapeutics's current Cash Flow from Operations (TTM) was -13.41.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Dec22) |
= | -15.423 | / | 28.064 | |
= | -0.54956528 |
ROA (Last Year) | = | Net Income | / | Total Assets (Dec21) |
= | -14.323 | / | 40.577 | |
= | -0.35298322 |
Indaptus Therapeutics's return on assets of this year was -0.54956528. Indaptus Therapeutics's return on assets of last year was -0.35298322.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Indaptus Therapeutics's current Net Income (TTM) was -15.42. Indaptus Therapeutics's current Cash Flow from Operations (TTM) was -13.41.
==> -13.41 > -15.42 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Dec23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Dec22 to Dec23 |
= | 0.073 | / | 20.9544 | |
= | 0.00348376 |
Gearing (Last Year: Dec22) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Dec21 to Dec22 |
= | 0 | / | 34.048 | |
= | 0 |
Indaptus Therapeutics's gearing of this year was 0.00348376. Indaptus Therapeutics's gearing of last year was 0.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Dec23) | = | Total Current Assets | / | Total Current Liabilities |
= | 13.995 | / | 2.774 | |
= | 5.04506128 |
Current Ratio (Last Year: Dec22) | = | Total Current Assets | / | Total Current Liabilities |
= | 27.244 | / | 3.433 | |
= | 7.93591611 |
Indaptus Therapeutics's current ratio of this year was 5.04506128. Indaptus Therapeutics's current ratio of last year was 7.93591611.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Indaptus Therapeutics's number of shares in issue this year was 8.401. Indaptus Therapeutics's number of shares in issue last year was 8.273.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 0 | / | 0 | |
= |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 0 | / | 0 | |
= |
Indaptus Therapeutics's gross margin of this year was . Indaptus Therapeutics's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Dec22) |
= | 0 | / | 28.064 | |
= | 0 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Dec21) |
= | 0 | / | 40.577 | |
= | 0 |
Indaptus Therapeutics's asset turnover of this year was 0. Indaptus Therapeutics's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 0 | + | 0 | + | 1 | + | 0 | + | 0 | + | 0 | + | 0 | + | 0 | |
= | 1 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Indaptus Therapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
Indaptus Therapeutics (NAS:INDP) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Indaptus Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Glen R. Anderson | 10 percent owner | 3274 ROSS ROAD, PALO ALTO CA 94303 |
Roger J. Waltzman | officer: Chief Medical Officer | C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
Robert Martell | director | 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Boyan Vesselinov Litchev | officer: Chief Medical Officer | 13357 RUSSET LEAF LN., SAN DIEGO CA 92129 |
Jeffrey A Meckler | director, officer: Chief Executive Officer | 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003 |
Walt Addison Linscott | officer: Chief Business Officer | 1860 MONTREAL ROAD, TUCKER GA 30084 |
Michael James Newman | director, 10 percent owner, officer: Chief Scientific Officer | C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
Mark John Gilbert | director | 13731 NORTHWOOD RD., NW, SEATTLE WA 98177 |
Brian O'callaghan | director | 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
Hoonmo Lee | director, 10 percent owner | C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512 |
Anthony J Maddaluna | director | PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017 |
William B Hayes | director | 231 MAPLE AVENUE, BURLINGTON NC 27215 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Hila Karah | director | 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900 |
Nir Sassi | officer: Chief Financial Officer | 3 ELUL STREET, APT. 6, MODIIN L3 7176397 |
From GuruFocus
By Value_Insider Value_Insider • 12-13-2022
By GuruFocusNews GuruFocusNews • 06-27-2022
By sperokesalga sperokesalga • 04-19-2023
By GuruFocusNews GuruFocusNews • 06-28-2022
By sperokesalga sperokesalga • 03-22-2023
By sperokesalga sperokesalga • 04-19-2023
By sperokesalga sperokesalga • 06-15-2023
By Marketwired • 09-26-2023
By Marketwired • 08-14-2023
By Marketwired • 08-10-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.